ABBV
AbbVie
October 14, 2026 · intraday
- Rarity
- 1.20
- Peak move
- +3.96%
- Float cap
- $484.4B
AbbVie is a research-based biopharmaceutical company that develops, manufactures and sells medicines across immunology, oncology, neuroscience, eye care and aesthetics. Its products include Skyrizi and Rinvoq for autoimmune conditions, Botox, Vraylar and Ubrelvy, blood-cancer drugs Imbruvica and Venclexta, and fillers and skincare brands. It sells to hospitals, physicians, pharmacies and consumers in more than 175 countries.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
7 events · 0 from SEC or newswire · 0 timed with the moveanalyst_ratingBMO Capital maintained a Buy rating on AbbVie with a $300 price target on October 12, 2026.
institutional_flowCourier Capital LLC cut its AbbVie stake by 82.6% in the third quarter, selling 13,119 shares and retaining 2,756 shares worth about $721,000, per its latest SEC filing.
- Key event
clinical_readoutAbbVie presented Phase 3 AFFIRM data at ACG 2026 showing subcutaneous SKYRIZI (risankizumab) produced higher rates of endoscopic remission and ulcer-free endoscopy versus placebo in patients with moderately to severely active Crohn's disease, with week-24 endoscopic remission in 35.8% versus 9.1% on placebo and 45.1% of advanced therapy-naive patients responding.
- Key event
guidance_changeAbbVie disclosed that Q3 2026 results will carry $216 million of pre-tax acquired IPR&D and milestone expense, cutting EPS by $0.11, and reset full-year 2026 adjusted diluted EPS guidance to $13.76-$13.96 and Q3 to $3.73-$3.77.
- Key event
regulatory_approvalChina's NMPA Center for Drug Evaluation accepted AbbVie's supplemental application for Risankizumab injection (acceptance no. JXSB2600191), filed October 13, 2026, with co-applicants Patheon Italia S.p.A. and AbbVie Ireland NL B.V.
analyst_ratingRBC Capital (analyst Trung Huynh) reiterated an Outperform rating on AbbVie with a $280 price target, reported October 13, 2026.
regulatory_approvalThe FDA granted two Breakthrough Therapy Designations to AbbVie's c-Met targeting cancer drug telisotuzumab adizutecan (Temab-A; ABBV-400), for refractory metastatic colorectal cancer in combination with bevacizumab and for c-Met-expressing EGFR wild-type non-squamous NSCLC as monotherapy.